Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High-Risk Companion Diagnostics Need IDEs Prior To Drug Trial, FDA Says

Executive Summary

Companies planning to co-develop an in vitro companion diagnostic alongside a therapeutic should be certain that the assay has been analytically validated and, if high risk, has won investigational device exemption before the drug trial begins, FDA warns in a July 14 draft guidance.

Advertisement

Related Content

Companion Diagnostics Guidance Finalized, But LDT Context Will Be Key

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS118793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel